| Tolvaptan | acute heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| hospitalisation for heart failure | 0.62 [0.33 1.14] | p=1.00 | 0 | 240 | 1 | Udelson, | | All cause death | 0.55 [0.19 1.53] | p=1.00 | 0 | 240 | 1 | Udelson, |
| Trial | Studied treatment | Control | Patients |
|---|
| EVEREST Clinical Status , 2007 | | | patients hospitalized with heart failure | | EVEREST Outcome, 2007 | | | patients hospitalized with heart failure | | Udelson, 2007 | tolvaptan 30 mg/day | placebo | patients with HF and reduced systolic function |
| |
| Tolvaptan | heart failure, in advanced heart failure | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| EVEREST Clinical Status , 2007 | | | patients hospitalized with heart failure | | EVEREST Outcome, 2007 | | | patients hospitalized with heart failure |
| |
| Tolvaptan | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| hospitalisation for heart failure | 0.62 [0.33 1.14] | p=1.00 | 0 | 240 | 1 | Udelson, | | All cause death | 0.55 [0.19 1.53] | p=1.00 | 0 | 240 | 1 | Udelson, |
| Trial | Studied treatment | Control | Patients |
|---|
| EVEREST Clinical Status , 2007 | | | patients hospitalized with heart failure | | EVEREST Outcome, 2007 | | | patients hospitalized with heart failure | | Udelson, 2007 | tolvaptan 30 mg/day | placebo | patients with HF and reduced systolic function |
| |
